Cite
HARVARD Citation
Yang, S. et al. (n.d.). A multicentre, multinational, randomized, placebo‐controlled, double‐blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15‐0444) in patients with type 2 diabetes. Diabetes, obesity & metabolism. 15 (5), pp. 410-416. [Online].